Last Updated: November 16, 2026

KANUMA Drug Profile

« Back to Dashboard


Summary for Tradename: KANUMA
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for KANUMA
Recent Clinical Trials for KANUMA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Alexion PharmaceuticalsPhase 3
Alexion PharmaceuticalsPhase 2/Phase 3
Alexion PharmaceuticalsPhase 1/Phase 2

See all KANUMA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KANUMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KANUMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for KANUMA Derived from Patent Text Search

These patents were obtained by searching patent claims

KANUMA Market Dynamics, Financial Trajectory, Patent Protection, and Competitive Risk

Last updated: October 28, 2026

KANUMA, the trade name for sebelipase alfa, is a recombinant lysosomal acid lipase replacement therapy marketed by Alexion, AstraZeneca’s rare-disease unit. The drug treats lysosomal acid lipase deficiency, an ultra-rare inherited metabolic disorder. Its commercial profile is defined by a small addressable population, chronic intravenous administration, high treatment value per patient, and limited near-term biosimilar pressure.

KANUMA has regulatory approval in the United States, European Union, United Kingdom, Japan, and other markets. U.S. orphan-drug exclusivity expired in 2022, but the product remains protected by biologic manufacturing complexity, limited patient identification, specialist distribution, and the absence of a disclosed commercial biosimilar competitor.

What is KANUMA and what disease does it treat?

KANUMA is sebelipase alfa, a recombinant form of human lysosomal acid lipase. It replaces the deficient enzyme in patients with lysosomal acid lipase deficiency, or LAL-D.

LAL-D causes abnormal accumulation of cholesteryl esters and triglycerides in organs and tissues. Clinical manifestations range from rapidly progressive disease in infants to chronic dyslipidemia, hepatic disease, fibrosis, cirrhosis, and cardiovascular risk in children and adults.

Product Detail
Active ingredient Sebelipase alfa
Brand KANUMA
Sponsor Alexion Pharmaceuticals, Inc., now part of AstraZeneca
U.S. application Biologics License Application 125581
Administration Intravenous infusion
U.S. approval December 2015
Main indication Lysosomal acid lipase deficiency
Initial U.S. orphan exclusivity Seven years from approval
Commercial category Ultra-orphan enzyme replacement therapy

The FDA approved KANUMA for infants with rapidly progressive LAL-D and for children and adults with LAL-D based on clinical studies showing improvements in survival, transaminases, lipid parameters, and hepatic disease markers. The U.S. label recommends weekly dosing for infants and every-other-week dosing for older patients, with dose escalation in selected cases. [1]

How large is the KANUMA market?

KANUMA addresses an ultra-orphan market with a small diagnosed population and substantial underdiagnosis. The commercial opportunity depends less on broad market expansion than on diagnosis rates, treatment persistence, and global reimbursement access.

The true prevalence of LAL-D is difficult to determine because historical diagnosis relied on clinical suspicion, liver biopsy, and biochemical testing. Modern dried-blood-spot testing has improved diagnosis, but many patients with adult-onset disease may be misclassified as having nonalcoholic fatty liver disease, familial hypercholesterolemia, or unexplained liver disease.

Market drivers

The main commercial drivers are:

  • Expanded genetic and enzyme testing.
  • Earlier pediatric diagnosis.
  • Greater recognition of unexplained hepatic disease.
  • Long-term treatment of adult patients.
  • Reimbursement for high-cost rare-disease therapies.
  • Geographic expansion into markets with specialist metabolic-care infrastructure.

Market constraints

The product faces structural limitations:

  • Very low patient prevalence.
  • Limited prescriber base.
  • Intravenous administration in specialized settings.
  • High dependence on enzyme replacement therapy centers.
  • Reimbursement scrutiny for lifelong treatment.
  • Potential treatment interruption caused by infusion reactions, access barriers, or patient burden.

KANUMA has no conventional mass-market growth path. Revenue depends on adding diagnosed patients and retaining them over long treatment periods.

What is the financial trajectory for KANUMA?

AstraZeneca does not consistently report KANUMA as a separately disclosed major revenue line in its public financial statements. The company reports detailed revenue for larger Alexion products, including SOLIRIS and ULTOMIRIS, while smaller rare-disease products may be grouped into broader categories.

This limits the reliability of any standalone KANUMA revenue estimate. Public financial disclosures support a conclusion of a durable but modest product franchise rather than a major growth driver for AstraZeneca.

Financial characteristic Assessment
Revenue scale Small relative to SOLIRIS and ULTOMIRIS
Growth profile Low-to-moderate, dependent on patient identification
Margin profile Potentially attractive because of biologic pricing and chronic use
Revenue volatility Lower than launch-stage products, but exposed to patient concentration
Strategic value Portfolio depth in ultra-rare metabolic disease
Main risk Limited addressable population and reimbursement pressure

Revenue trajectory before and after the Alexion acquisition

Alexion acquired Synageva in 2015 for approximately $8.4 billion. The transaction gave Alexion access to KANUMA and the investigational therapy sebelipase alfa’s commercial infrastructure, alongside Synageva’s metabolic-disease platform. [2]

AstraZeneca acquired Alexion in 2021 for approximately $39 billion. KANUMA became part of AstraZeneca’s rare-disease portfolio, which also includes SOLIRIS, ULTOMIRIS, STRensiq, and other metabolic or complement-focused products. [3]

The acquisition structure matters for financial analysis. KANUMA is strategically important as part of a rare-disease portfolio, but it is not individually material to AstraZeneca’s consolidated revenue in the same way as ULTOMIRIS or FARXIGA.

What determines KANUMA revenue growth?

KANUMA revenue is primarily a function of:

  1. Number of diagnosed patients.
  2. Percentage receiving treatment.
  3. Dosing frequency and dose escalation.
  4. Treatment persistence.
  5. Net price after rebates and government discounts.
  6. Launch timing and reimbursement in each country.

Price increases alone are unlikely to produce sustained growth in a market with a small patient pool and high payer sensitivity. Patient-finding programs and diagnostic testing are more important commercial levers.

When did KANUMA lose U.S. orphan-drug exclusivity?

KANUMA received U.S. orphan-drug designation. The FDA granted seven years of orphan-drug exclusivity following approval in December 2015. That exclusivity period ended in December 2022, assuming the standard period was not extended or modified by a regulatory action.

Orphan-drug exclusivity prevents approval of the same drug for the same indication during the protected period. It does not block all competing products, and it does not replace patent protection.

Protection Approximate status
U.S. orphan-drug exclusivity Expired in December 2022
Biologic reference-product exclusivity Twelve years from licensure under the BPCIA framework, subject to regulatory interpretation and reference-product treatment
Patent protection Depends on issued patents, terminal disclaimers, continuations, and jurisdiction
Regulatory exclusivity in Europe Separate EU orphan and market-exclusivity rules apply
Pediatric extension Requires confirmation from the applicable regulatory record

The end of orphan exclusivity does not create automatic generic or biosimilar entry. A competing biologic would still need to establish an appropriate regulatory pathway, manufacture a comparable enzyme, obtain regulatory approval, and secure reimbursement.

What is the FDA regulatory and Orange Book status of KANUMA?

KANUMA is a biologic licensed under a BLA, not a conventional small-molecule drug approved under an NDA. It therefore is not protected through the Orange Book in the same way as an NDA product.

The relevant regulatory framework is the Public Health Service Act and the Biologics Price Competition and Innovation Act. Reference biologics and biosimilar products are tracked through FDA biologic records, including the Purple Book framework, rather than relying on standard Orange Book patent-listing mechanics. [4]

FDA status

Regulatory issue KANUMA status
FDA product type Biologic
Approval pathway BLA
Reference product Yes
Biosimilar pathway Potentially available to future competitors
Orange Book listing Not the principal patent-record mechanism
FDA-approved biosimilar No publicly identified U.S. biosimilar through June 2024
Interchangeable biosimilar None publicly identified through June 2024

The distinction is commercially important. Patent certifications such as Paragraph IV challenges apply to NDA products listed in the Orange Book. They do not map directly onto a biologic BLA. A competitor seeking approval would more likely use the biosimilar pathway or pursue a separate full BLA.

What patents protect KANUMA?

KANUMA’s protection is likely based on a combination of biologic composition, recombinant production, formulation, dosing, and manufacturing rights. The exact remaining term depends on the relevant patent families, patent-term adjustments, terminal disclaimers, continuations, and country-specific prosecution.

Potential protection categories include:

  • Recombinant lysosomal acid lipase molecules.
  • Cell lines and expression systems.
  • Protein production and purification methods.
  • Formulation and stability technology.
  • Dosing regimens for infantile or late-onset LAL-D.
  • Methods of treating hepatic and lipid abnormalities.
  • Manufacturing controls for a complex glycoprotein enzyme.

Because KANUMA is a recombinant enzyme, manufacturing know-how can be as important as issued patent claims. A biosimilar developer would need to reproduce a biologically active enzyme with suitable glycosylation, purity, potency, stability, and immunogenicity characteristics.

How strong is the KANUMA patent estate?

The patent estate is commercially meaningful but less likely to provide an indefinite barrier than the manufacturing platform.

Patent strength is highest where claims cover:

  • The specific recombinant protein sequence.
  • Validated production-cell systems.
  • Narrow therapeutic dosing regimens.
  • Commercially necessary formulation attributes.
  • Manufacturing steps that are difficult to design around.

Patent strength is weaker where claims cover broad treatment concepts, routine dosing ranges, or methods that can be avoided through a different development protocol.

Publicly disclosed patent information does not indicate a major, active U.S. patent dispute surrounding KANUMA comparable to litigation involving major small-molecule products. The absence of a disclosed biosimilar program reduces immediate litigation risk.

Are there Paragraph IV challenges or biosimilar threats to KANUMA?

No material public Paragraph IV challenge has been identified because KANUMA is a biologic and is not regulated through the standard Orange Book generic pathway.

No commercial U.S. biosimilar competitor was publicly identified through June 2024. Biosimilar risk remains technically possible but commercially limited by the small patient population and the complexity of enzyme replacement manufacturing.

Biosimilar entry barriers

A prospective competitor would face:

  • Limited clinical recruitment capacity.
  • Difficulty demonstrating analytical similarity.
  • Potential need for comparative pharmacokinetic or pharmacodynamic data.
  • Immunogenicity assessment.
  • Specialized manufacturing requirements.
  • High development cost relative to the addressable population.
  • Payer uncertainty over interchangeability and substitution.
  • Limited pharmacy-channel substitution because KANUMA is infused.

The first entrant could still pursue a premium-priced biosimilar strategy if it obtains preferred reimbursement or contracts with major treatment centers. However, automatic substitution is less likely than for many self-administered biologics.

What competitive products challenge KANUMA?

KANUMA has no direct enzyme-replacement competitor approved specifically for LAL-D. Its practical competition comes from delayed diagnosis, supportive treatment, off-label management, and alternative interventions for complications.

Competitive category Relationship to KANUMA
Statins and lipid-lowering drugs May address dyslipidemia but do not replace deficient enzyme
Hepatology care Treats complications rather than the underlying defect
Liver transplantation Relevant only for advanced irreversible liver disease
Hematopoietic stem-cell transplantation Not a standard substitute for approved KANUMA therapy
Future gene therapy Potential long-term competitive threat, but no established approved substitute
Biosimilars Possible future direct competition

The absence of an approved alternative supports KANUMA’s pricing and treatment position. It also increases payer leverage because the product’s high cost is concentrated in a very small population.

What licensing deals and ownership changes affect KANUMA?

KANUMA originated at Synageva BioPharma. Alexion acquired Synageva in 2015, and AstraZeneca acquired Alexion in 2021.

Date Transaction or milestone
2015 Alexion completed acquisition of Synageva
2015 FDA approved KANUMA
2015-2022 U.S. orphan-drug exclusivity period
2021 AstraZeneca completed acquisition of Alexion
2022 U.S. orphan-drug exclusivity expired
Through June 2024 No major public KANUMA-specific licensing transaction or commercial biosimilar launch identified

The ownership chain gives AstraZeneca control over commercial strategy, manufacturing, regulatory submissions, and intellectual-property enforcement.

What litigation and settlement risks affect KANUMA?

No major publicly reported U.S. patent litigation or Paragraph IV settlement involving KANUMA was identified through June 2024.

The main future litigation scenarios would involve:

  • A biosimilar applicant challenging formulation or manufacturing patents.
  • A patent-infringement claim involving recombinant enzyme production.
  • A dispute over patent listing or patent-term calculations.
  • A regulatory challenge involving biosimilar interchangeability.
  • Contract disputes with specialty distributors or treatment centers.

A settlement could permit an early biosimilar launch before all asserted patents expire. In a market this small, the commercial value of a settlement would depend more on reimbursement access and manufacturing capacity than on broad retail substitution.

What generic launch scenarios exist for KANUMA?

Three launch scenarios are plausible.

Scenario 1: No near-term competitor

This is the base case. KANUMA retains the market because the patient pool is small, no biosimilar program reaches late-stage development, and manufacturing economics discourage entry.

Scenario 2: One biosimilar entrant

A single biosimilar could enter with a modest discount, targeting hospitals and metabolic-disease centers. The impact would likely be gradual because patients receive chronic infusions and switching requires physician and payer coordination.

Scenario 3: Alternative biologic or gene therapy

A new enzyme-replacement product or gene therapy could create stronger competitive pressure. Such a product would need to demonstrate durable efficacy, acceptable safety, and a reimbursement model that supports a rare-disease population.

How does KANUMA compare with AstraZeneca’s other rare-disease products?

Product Disease area Administration Commercial scale Competitive pressure
KANUMA LAL-D IV infusion Small Low direct competition
STRENSIQ Hypophosphatasia Subcutaneous injection Larger ultra-rare opportunity Moderate future biologic risk
SOLIRIS Complement-mediated diseases IV infusion Large Higher biosimilar and class competition
ULTOMIRIS Complement-mediated diseases IV or subcutaneous, depending on indication Major growth product High strategic and competitive importance

KANUMA is strategically complementary to AstraZeneca’s rare-disease portfolio. Its value lies in durable treatment revenue, specialist infrastructure, and diagnostic expansion rather than blockbuster scale.

What is the investment and commercial outlook for KANUMA?

KANUMA’s outlook is stable but constrained. The product has:

  • Strong therapeutic differentiation.
  • No approved direct competitor.
  • High barriers to biologic replication.
  • Chronic treatment economics.
  • A small and difficult-to-identify patient population.
  • Limited standalone revenue disclosure.
  • Reduced regulatory exclusivity after 2022.

The most likely financial trajectory is low-single-digit or moderate growth driven by diagnosis and geographic penetration, followed by a plateau as the diagnosed population matures. A sharp revenue decline is unlikely without a biosimilar, safety issue, reimbursement reversal, or a superior gene-therapy alternative.

Key Takeaways

  • KANUMA is sebelipase alfa, an enzyme replacement therapy for LAL-D.
  • It is marketed by Alexion, a wholly owned AstraZeneca business.
  • U.S. FDA approval occurred in December 2015.
  • U.S. orphan-drug exclusivity expired in December 2022.
  • KANUMA is a biologic BLA product, so the Orange Book and Paragraph IV framework do not directly apply.
  • No commercial U.S. biosimilar or major KANUMA patent challenge was publicly identified through June 2024.
  • The market is small, chronic, specialist-driven, and dependent on improved diagnosis.
  • Manufacturing complexity and limited patient volume reduce near-term biosimilar risk.
  • AstraZeneca does not consistently disclose KANUMA revenue as a standalone major product line.
  • The product is more important as a durable ultra-rare portfolio asset than as a material consolidated revenue driver.

FAQs

Is KANUMA a biologic or a generic drug?

KANUMA is a biologic enzyme replacement therapy approved under a BLA. It is not a conventional generic drug.

Can KANUMA be automatically substituted with a biosimilar?

No U.S. biosimilar or interchangeable biosimilar was publicly identified through June 2024. Automatic substitution would require an FDA-designated interchangeable biosimilar and applicable state-law authority.

Does KANUMA have Orange Book patents?

KANUMA is not principally governed by the Orange Book because it is a BLA biologic. The relevant regulatory and patent framework differs from that used for NDA-approved small molecules.

What is the biggest commercial risk to KANUMA?

The largest commercial risk is the small diagnosed population. A biosimilar, reimbursement restriction, manufacturing disruption, or competing gene therapy could increase risk, but diagnosis and market size are the central constraints.

Who owns the KANUMA patents?

The commercial rights are associated with Alexion Pharmaceuticals and its parent AstraZeneca following Alexion’s acquisition of Synageva and AstraZeneca’s acquisition of Alexion. Patent ownership may vary by jurisdiction and patent family.

References

  1. U.S. Food and Drug Administration. (2015). KANUMA (sebelipase alfa) prescribing information. FDA.

  2. Alexion Pharmaceuticals, Inc. (2015). Alexion completes acquisition of Synageva BioPharma Corp. Company announcement.

  3. AstraZeneca. (2021). AstraZeneca completes acquisition of Alexion. Company announcement.

  4. U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. FDA.

  5. European Medicines Agency. (2015). Kanuma: EPAR product information. EMA.

  6. AstraZeneca. (2023). Annual report and Form 20-F for the year ended December 31, 2023. AstraZeneca.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.